Nusinersen and risdiplam are U.S. Food and Drug Administration (FDA)‐approved treatments for spinal muscular atrophy (SMA). No head‐to‐head clinical trials to assess efficacy exist. Observational studies are needed to determine if transitioning to risdiplam is safe and efficacious.

Transitioning from nusinersen to risdiplam for spinal muscular atrophy is not currently studied, and more observational studies are needed to determine its safety and efficacy.

Paper

Transitioning From Nusinersen to Risdiplam for Spinal Muscular Atrophy in Clinical Practice: A Single‐Center Experience

References

Citations